PLUS1
Best deals to access real time data! |
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last $ 0.16 ◊ 0.00 (0.00%) | |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Phio Pharmaceuticals Corporation | PHIO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.005 | 3.23% | 0.16 | 0.1671 | 0.1475 | 0.1475 | 0.155 | 19:57:56 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 0.152 | 0.16 | 0.008 | 5.0% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 849 | 1,380,962 | $ 0.159436 | $ 220,175 | 1,371,511 | 0.097 - 0.54 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:56:46 | formt | 440 | $ 0.16 | USD |
Phio Pharmaceuticals Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 5.89M | 36.82M | $ -7.36M | -1.20 | 0.60 | 33.29M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 5.00 | 9.70% |
Phio Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 12/06/2019 | 17:16 | Edgar (US Regulatory) | Amended Current Report Filing (8-k/a) |
| 11/22/2019 | 17:23 | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) |
| 11/20/2019 | 06:02 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 11/18/2019 | 17:24 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) |
| 11/18/2019 | 07:29 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) |
| 11/13/2019 | 17:26 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) |
| 11/12/2019 | 17:21 | Edgar (US Regulatory) | Current Report Filing (8-k) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PHIO Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.148 | 0.1789 | 0.132 | 0.1562577 | 1,282,187 | 0.012 | 8.11% |
| 1 Month | 0.29 | 0.3205 | 0.097 | 0.1400211 | 2,034,196 | -0.13 | -44.83% |
| 3 Months | 0.32 | 0.364 | 0.097 | 0.1639364 | 817,431 | -0.16 | -50.0% |
| 6 Months | 0.4099 | 0.448 | 0.097 | 0.1920098 | 436,324 | -0.2499 | -60.97% |
| 1 Year | 0.38 | 0.54 | 0.097 | 0.3200074 | 488,902 | -0.22 | -57.89% |
| 3 Years | 0.39 | 0.54 | 0.097 | 0.3214829 | 495,093 | -0.23 | -58.97% |
| 5 Years | 0.39 | 0.54 | 0.097 | 0.3214829 | 495,093 | -0.23 | -58.97% |
Phio Pharmaceuticals Description
| Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immunooncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The clinical development program of the company includes RXI-109, a sd-rxRNA for the treatment of dermal and ocular scarring, and Samcyprone, for the treatment of warts. The pipeline product of the company includes RXI-109, Immuno-oncology cell therapy, samcyprone, RXI-231, and RXI-185. The pipeline programs focus on dermatology, including cosmetic product development, ophthalmology, and cell-based cancer immunotherapy. |
